Zenas BioPharma and Royalty Pharma Enter into Obexelimab Funding Agreement for up to $300 Million

- Initial $75 million to fund the potential U.S. commercial launch of obexelimab for the treatment of IgG4-Related Disease -

- Additional $150 million associated with the upcoming results of the obexelimab Phase 3 INDIGO trial and FDA approval for the treatment of IgG4-Related Disease -

Read more at globenewswire.com